Press Releases October 1, 2026 06:00 AM

Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies

Kestra Medical Technologies earns prestigious five-star rating from Newsweek among America's top mid-market companies

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
KMTS

Kestra Medical Technologies, a Nasdaq-listed wearable medical device company, received a five-star rating on Newsweek's inaugural list of America's Greatest Mid-Market Companies, recognized for its innovative cardiac protection products and rapid commercial growth in the medical equipment manufacturing sector.

Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market Companies
KMTS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Kestra is the only company in its category to earn a five-star rating among 100 mid-market companies evaluated by Newsweek.
  • The company's flagship product, the ASSURE® WCD, aids clinicians in protecting patients during cardiac risk and recovery phases, underpinning rapid business growth.
  • Newsweek’s assessment considered financial performance, workforce experience, innovation, and sustainability, highlighting Kestra's overall strength and market positioning.

KIRKLAND, Wash., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, has earned a five-star rating on Newsweek’s list of America’s Greatest Mid-Market Companies 2026. Only 30 of the 100 honorees earned five stars, and Kestra was the only company in the Medical Equipment Manufacturing category to receive that rating.

“In less than a decade, our team brought the ASSURE® WCD to market and built a rapidly growing commercial business, giving clinicians a differentiated choice for protecting patients during periods of cardiac risk and recovery,” said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. “This five-star rating reflects the strength of the Kestra team and the company we’ve built. We’re now positioned to extend our reach, advance our Cardiac Recovery System® platform, and pursue a bigger vision for wearable cardiac protection.”

For its inaugural ranking, Newsweek and Plant-A Insights Group assessed publicly traded U.S. mid-market companies across financial performance, workforce experience, innovation, and sustainability. Their analysis drew on business metrics, third-party workforce data, and more than 2.7 million company reviews.

“Newsweek’s ranking of America’s Greatest Mid-Market Companies recognizes businesses that are proving that meaningful growth and lasting impact aren’t limited to the largest corporations,” added Ryan Kinney, Senior Vice President, Newsweek. “The ranking shines a spotlight on midsize companies that are strengthening their industries, creating opportunities for team members and customers, and demonstrating the ambition and resilience needed to succeed in a competitive marketplace.”

About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com. 

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed or implied by these statements. For a discussion of factors that could cause actual results to differ, see Kestra's filings with the U.S. Securities and Exchange Commission. Kestra undertakes no obligation to update any forward-looking statements except as required by law.


Risks

  • Forward-looking statements indicate potential risks and uncertainties that could materially affect actual results.
  • Competition in the wearable medical device and digital healthcare sector may impact growth and market share.
  • Regulatory and market acceptance challenges inherent to medical device commercialization could affect operational performance.

More from Press Releases

Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split Nov 4, 2026